New therapies on the horizon.
Statins have proved to be potent drugs for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, because the response to current statin therapy regimens is not always sufficient to reach defined goal levels, additional drugs to lower LDL-C are needed. New drugs may soon be available to lower LDL-C levels by mechanisms that differ from those of the statins. Among these new agents are a bile acid binding resin, inhibitors of bile acid transport, inhibitors of cholesterol transport, inhibitors of cholesterol esterification, and triglyceride-lowering agents.
Brown
W V
WV
D000499:Allylamine / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000378:metabolism / Q000627:therapeutic use*; D001647:Bile Acids and Salts / Q000378:metabolism; D001692:Biological Transport; D002784:Cholesterol / Q000378:metabolism; D002792:Cholestyramine Resin / Q000378:metabolism / Q000627:therapeutic use; D000069472:Colesevelam Hydrochloride; D004951:Esterification; D005464:Fluorobenzenes / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007408:Intestinal Absorption; D008077:Lipoproteins, LDL / Q000097:blood*; D011743:Pyrimidines; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides; D014481:United States
D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D005464:Fluorobenzenes; D008077:Lipoproteins, LDL; D011743:Pyrimidines; D013449:Sulfonamides; D002792:Cholestyramine Resin; D000499:Allylamine; D000068718:Rosuvastatin Calcium; D002784:Cholesterol; D000069472:Colesevelam Hydrochloride